Home > Boards > US Listed > Medical - Drugs > Arbutus Biopharma Corporation (ABUS)

Scroll down to Providence Therapeutics to learn more

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Purple Wonder Member Profile
 
Followed By 62
Posts 4,904
Boards Moderated 0
Alias Born 08/08/08
160x600 placeholder
Arbutus Bio slips 4% as Q1 revenue trails consensus Seeking Alpha - 5/5/2021 9:11:30 AM
Arbutus Biopharma EPS beats by $0.02, misses on revenue Seeking Alpha - 5/5/2021 7:33:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2021 7:32:58 AM
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/5/2021 7:30:00 AM
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO PR Newswire (Canada) - 5/3/2021 7:00:00 AM
Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update GlobeNewswire Inc. - 4/28/2021 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/8/2021 2:54:52 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/8/2021 2:53:14 PM
Arbutus shares rise after SARS-CoV-2 research deal Seeking Alpha - 4/1/2021 8:22:13 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2021 7:33:13 AM
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement GlobeNewswire Inc. - 4/1/2021 7:30:00 AM
Arbutus Gets Go Ahead To Kick Off Phase 1a/1b Clinical Trial Of AB-836 TipRanks - 3/17/2021 7:33:18 AM
Arbutus receives regulatory approval to start early-stage HBV trial Seeking Alpha - 3/16/2021 7:38:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 7:33:27 AM
Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the T... GlobeNewswire Inc. - 3/16/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/4/2021 5:13:26 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/4/2021 5:06:25 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/4/2021 4:34:23 PM
Arbutus Biopharma EPS misses by $0.01, beats on revenue Seeking Alpha - 3/4/2021 7:38:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/4/2021 7:32:54 AM
Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 3/4/2021 7:30:00 AM
Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference GlobeNewswire Inc. - 3/2/2021 8:00:00 AM
Assembly Bio, Arbutus Bio commence trial of triple combo therapy in hepatitis B Seeking Alpha - 2/26/2021 7:52:37 AM
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of... GlobeNewswire Inc. - 2/26/2021 7:30:00 AM
Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update GlobeNewswire Inc. - 2/22/2021 8:00:00 AM
Purple Wonder   Monday, 12/28/20 09:25:03 AM
Re: Purple Wonder post# 6218
Post # of 6310 
Scroll down to Providence Therapeutics to learn more about their Covid-19 vaccine candidate. The most interesting part for me is:

The mRNA sequence, which is manufactured at Providence's Toronto plant, will be packaged in microscopic containers called lipid nanoparticles (LNPs) for injection into the body. The LNPs are made by Vancouver-based Genevant and are already used in an approved mRNA-based medication.

https://www.cbc.ca/news/technology/canadian-vaccine-candidates-covid-coronavirus-1.5764874

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences